CN115969928A - Traditional Chinese medicine composition for treating chronic heart failure and application thereof - Google Patents
Traditional Chinese medicine composition for treating chronic heart failure and application thereof Download PDFInfo
- Publication number
- CN115969928A CN115969928A CN202211537001.0A CN202211537001A CN115969928A CN 115969928 A CN115969928 A CN 115969928A CN 202211537001 A CN202211537001 A CN 202211537001A CN 115969928 A CN115969928 A CN 115969928A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart failure
- chinese medicine
- traditional chinese
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 235000006533 astragalus Nutrition 0.000 claims abstract description 21
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 20
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 244000171085 Polyporus umbellatus Species 0.000 claims abstract description 14
- 235000004837 Polyporus umbellatus Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 6
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 5
- 241001061264 Astragalus Species 0.000 claims description 15
- 210000004233 talus Anatomy 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 10
- 241000222640 Polyporus Species 0.000 claims description 9
- 241000801118 Lepidium Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 18
- 208000004880 Polyuria Diseases 0.000 abstract description 12
- 230000035619 diuresis Effects 0.000 abstract description 12
- 206010016807 Fluid retention Diseases 0.000 abstract description 6
- 230000001939 inductive effect Effects 0.000 abstract description 6
- 230000008961 swelling Effects 0.000 abstract description 3
- 206010019280 Heart failures Diseases 0.000 description 30
- 241000700159 Rattus Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 240000003582 Platycodon grandiflorus Species 0.000 description 16
- 230000004217 heart function Effects 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 11
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 10
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 10
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 102400001263 NT-proBNP Human genes 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011947 six minute walk test Methods 0.000 description 5
- 241000906579 Actaea cimicifuga Species 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 241000605447 Anemarrhena Species 0.000 description 4
- 241000202726 Bupleurum Species 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 229930191283 anemarrhena Natural products 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 241000320892 Clerodendrum phlomidis Species 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 229940125365 angiotensin receptor blocker-neprilysin inhibitor Drugs 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000132012 Atractylodes Species 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 244000062995 Cassia occidentalis Species 0.000 description 1
- 235000001948 Cassia occidentalis Nutrition 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010034487 Pericarditis constrictive Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241000017433 Schefflera heptaphylla Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000000839 constrictive pericarditis Diseases 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating chronic heart failure, which is prepared from the following raw material medicines in parts by weight: 14-22 parts of astragalus mongholicus, 11-19 parts of semen lepidii, 11-19 parts of polyporus umbellatus, 6-14 parts of rhizoma anemarrhenae, 2-10 parts of radix bupleuri, 2-10 parts of platycodon grandiflorum and 1-8 parts of rhizoma cimicifugae. The invention also provides application of the medicine in preparing a medicine for treating chronic heart failure, the traditional Chinese medicine composition has a good treatment effect on qi-deficiency and water-retention type chronic heart failure, and meanwhile, the formula has the effects of tonifying qi, lifting yang, inducing diuresis, excreting dampness and reducing swelling together, and has the effects of lifting qi, lifting yang, lifting dampness and inducing diuresis.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic heart failure and application thereof.
Background
Chronic Heart Failure (CHF) is a common complex and serious clinical syndrome with a poor overall prognosis, and how to reduce the incidence, disability rate and mortality of heart failure has been a global medical problem. Heart failure is a progressively aggravating condition in which the structure and function of the heart are constantly worsening even if the heart is not newly damaged in a perceptible manner, and studies have shown that about 60% of patients with heart failure die from sudden death, and that with increasing severity of heart failure, there are increasing patients who die as a result of worsening of heart failure.
The ancient book of traditional Chinese medicine has no name of heart failure, and the names of diseases related to the heart failure are firstly seen in the 'internal classic', and from the 'heart distension, dysphoria, short breath, uneasiness in lying down' and 'heart impediment, obstructed pulse, heart bulging, upward qi and asthma', the 'heart distension' and the 'heart impediment' can be easily found to be classified into the heart failure according to the expression. Zhang Zhongjing further provides the disease name of heart water on the basis, and the 'Jinkui Yao L' is recorded in the book: the symptoms of the heart-water patient are closer to the congestive heart failure in modern medicine, and the pathogenesis of the heart-water patient is very similar to the theory of heart-kidney mechanism in early stage of heart failure. The clinical manifestations characteristic of heart failure are dyspnea, edema, increased heart rate, etc. Ancient Chinese medicine does not have the symptoms corresponding to heart failure, and from the clinical manifestations, heart failure mainly belongs to ' asthma syndrome ', ' edema ', palpitation ' and the like of Chinese medicine.
The traditional Chinese medicine has a long history and definite curative effect on the diagnosis and treatment of heart failure related diseases, particularly, through the practice and research of the traditional Chinese medicine for treating the heart failure in recent years, the traditional Chinese medicine has basically achieved consensus on the core pathogenesis (qi, yin and yang deficiency as the basis and blood nodule and water retention as the target) of the heart failure, and the traditional Chinese medicine also becomes a widely recognized basic treatment method for treating the heart failure by tonifying qi, nourishing yin, warming yang, activating blood and inducing diuresis. Aiming at the pathogenesis characteristics of heart failure with deficiency and marked excess, the basic treatment principle of heart failure is to tonify heart qi, regulate yin and yang, activate blood and promote diuresis, expel pathogenic factors as assistance, tonify deficiency without forgetting to expel pathogenic factors, and expel pathogenic factors with emphasis on nourishing vital qi. In recent years, the treatment of heart failure has been focused on heart qi tonifying, yang warming, qi tonifying, blood circulation promoting and diuresis promoting, and qi tonifying, yin nourishing, blood circulation promoting and diuresis promoting.
Chinese patent CN115282219A, published as 2022.11.04 discloses a traditional Chinese medicine composition for treating chronic heart failure, a preparation method and application thereof, wherein the traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 10-30 parts of cassia twig, 10-30 parts of polyporus umbellatus, 10-30 parts of poria cocos, 10-30 parts of rhizoma alismatis, 10-30 parts of bighead atractylodes rhizome, 10-30 parts of moutan bark, 10-30 parts of peach kernel and 10-30 parts of peony root, wherein the traditional Chinese medicine formula has the efficacies of warming and activating heart yang, promoting blood circulation and promoting diuresis, mainly treats yang deficiency and blood stasis and water retention type chronic heart failure, and simultaneously has the effects of improving heart function, improving life quality of patients and the like. Chinese patent CN113559223A, published Japanese 2021.10.29 discloses a traditional Chinese medicine compound composition for treating chronic heart failure, which comprises the following components: 20-60 parts of semen lepidii, 20-60 parts of Chinese date, 10-30 parts of curcuma zedoary, 10-30 parts of pollen typhae, 30-90 parts of raw astragalus membranaceus, 20-60 parts of salvia miltiorrhiza, 30-90 parts of rhodiola rosea, 10-30 parts of fructus liquidambaris, 20-60 parts of plantain herb, 10-30 parts of poria cocos, 20-60 parts of fried bighead atractylodes rhizome, 20-60 parts of radix polygonati officinalis, 10-30 parts of cassia twig and 10-30 parts of fructus broussonetiae. The traditional Chinese medicine compound composition for treating chronic heart failure has a treatment effect on chronic heart failure, has the effects of purging lung, removing water retention, tonifying qi, invigorating spleen, warming yang and removing stasis, can obviously improve clinical symptoms of patients with heart failure, improve cardiac function grading and reduce blood plasma B-type brain natriuretic peptide and other heart failure indexes, and is small in toxic and side effects after long-term administration and safe and reliable in medication. The traditional Chinese medicine composition has more medicinal ingredients, increases the preparation procedures of the medicine, and is more complicated, so that the preparation of the traditional Chinese medicine composition which has obvious effect and moderate medicinal ingredient number and is used for treating chronic heart failure is necessary.
However, the traditional Chinese medicine composition for treating chronic heart failure has not been reported at present.
Disclosure of Invention
The first purpose of the present invention is to provide a Chinese medicine composition for overcoming the defects in the prior art.
The second purpose of the invention is to provide the application of the traditional Chinese medicine composition.
In order to realize the first purpose, the invention adopts the technical scheme that:
a traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw material medicines in parts by weight: 14-22 parts of astragalus mongholicus, 11-19 parts of semen lepidii, 11-19 parts of polyporus umbellatus, 6-14 parts of rhizoma anemarrhenae, 2-10 parts of radix bupleuri, 2-10 parts of platycodon grandiflorum and 1-8 parts of rhizoma cimicifugae.
As a preferred example, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 16-20 parts of astragalus membranaceus, 13-17 parts of semen lepidii, 13-17 parts of polyporus umbellatus, 8-12 parts of rhizoma anemarrhenae, 4-8 parts of radix bupleuri, 4-8 parts of platycodon grandiflorum and 2-6 parts of rhizoma cimicifugae.
As a preferred example, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 18 parts of astragalus, 15 parts of pepperweed seed, 15 parts of polyporus, 10 parts of rhizoma anemarrhenae, 6 parts of radix bupleuri, 6 parts of platycodon grandiflorum and 4 parts of cimicifugae foetidae.
In order to achieve the second object, the invention adopts the technical scheme that:
the application of the traditional Chinese medicine composition in preparing a medicine for treating chronic heart failure.
More preferably, the chronic heart failure is qi-deficiency and water-retention type chronic heart failure.
The traditional Chinese medicines in the formula have the following effects:
astragalus root, radix astragali, replenishing qi and elevating, invigorating spleen and tonifying lung, semen lepidii, purging lung and relieving asthma, inducing diuresis and relieving swelling, the heart and lung of both are concocted and mainly attack upper energizer, and is the monarch drug; the polyporus umbellatus is used for promoting diuresis and eliminating dampness, and strengthening the effect of promoting diuresis of monarch drugs, and is a ministerial drug; radix bupleuri and rhizoma cimicifugae are used as adjuvant drugs, the effects of radix platycodonis on yellow millet are that the radix bupleuri and rhizoma cimicifugae respectively take away shaoyang and yangming to guide atmosphere upward, rhizoma anemarrhenae is cool and moisten into kidney and ascend to descend, and the whole formula is prepared. The whole formula has the effects of tonifying qi, lifting yang, lifting sinking, inducing diuresis, excreting dampness and reducing swelling, and has the effects of lifting sinking and inducing diuresis.
[ detailed description ] embodiments
The following provides a detailed description of specific embodiments of the present invention.
EXAMPLE 1 pharmaceutical composition for the treatment of Chronic Heart failure
18 parts of astragalus, 15 parts of semen lepidii, 15 parts of polyporus, 10 parts of rhizoma anemarrhenae, 6 parts of radix bupleuri, 6 parts of platycodon grandiflorum and 4 parts of rhizoma cimicifugae.
EXAMPLE 2 pharmaceutical composition for the treatment of Chronic Heart failure
18 parts of astragalus, 13 parts of semen lepidii, 17 parts of polyporus, 6 parts of rhizoma anemarrhenae, 10 parts of radix bupleuri, 6 parts of platycodon grandiflorum and 2 parts of cimicifugae foetidae.
EXAMPLE 3 pharmaceutical composition for treatment of Chronic Heart failure
16 parts of astragalus, 17 parts of semen lepidii, 11 parts of polyporus, 14 parts of rhizoma anemarrhenae, 6 parts of radix bupleuri, 4 parts of platycodon grandiflorum and 6 parts of cimicifugae foetidae.
Example 4 pharmaceutical composition for the treatment of chronic Heart failure (IV)
20 parts of astragalus, 11 parts of pepperweed seed, 19 parts of polyporus umbellatus, 10 parts of anemarrhena, 4 parts of bupleurum, 8 parts of balloonflower root and 1 part of cimicifuga foetida.
EXAMPLE 5 pharmaceutical composition for treatment of Chronic Heart failure (five)
14 parts of astragalus, 19 parts of semen lepidii, 15 parts of polyporus, 8 parts of rhizoma anemarrhenae, 8 parts of radix bupleuri, 2 parts of platycodon grandiflorum and 8 parts of rhizoma cimicifugae.
EXAMPLE 6 pharmaceutical composition (VI) for the treatment of Chronic Heart failure
22 parts of astragalus, 15 parts of pepperweed seed, 13 parts of polyporus umbellatus, 12 parts of anemarrhena, 2 parts of bupleurum, 10 parts of balloonflower root and 4 parts of cimicifuga foetida.
EXAMPLE 7 pharmaceutical composition (seven) for the treatment of chronic Heart failure
18 parts of astragalus, 17 parts of pepperweed seed, 11 parts of polyporus umbellatus, 14 parts of anemarrhena, 6 parts of bupleurum, 4 parts of platycodon root and 6 parts of cimicifuga foetida.
EXAMPLE 8 pharmaceutical composition for treatment of Chronic Heart failure (eight)
16 parts of astragalus, 11 parts of semen lepidii, 19 parts of polyporus, 10 parts of rhizoma anemarrhenae, 4 parts of radix bupleuri, 8 parts of platycodon grandiflorum and 1 part of cimicifugae foetidae.
EXAMPLE 9 pharmaceutical composition for treatment of Chronic Heart failure (nine)
20 parts of astragalus, 19 parts of semen lepidii, 15 parts of polyporus, 8 parts of rhizoma anemarrhenae, 8 parts of radix bupleuri, 2 parts of platycodon grandiflorum and 8 parts of rhizoma cimicifugae.
EXAMPLE 10 pharmaceutical composition (Ten) for the treatment of chronic heart failure
14 parts of astragalus, 15 parts of semen lepidii, 13 parts of polyporus umbellatus, 12 parts of rhizoma anemarrhenae, 2 parts of radix bupleuri, 10 parts of platycodon grandiflorum and 4 parts of rhizoma cimicifugae.
EXAMPLE 11 pharmaceutical composition for treatment of Chronic Heart failure (eleven)
22 parts of astragalus, 13 parts of pepperweed seed, 17 parts of polyporus umbellatus, 6 parts of anemarrhena, 10 parts of bupleurum, 6 parts of balloonflower root and 2 parts of cimicifuga foetida.
It should be noted that the conventional method for decocting the raw materials described in examples 1 to 11 is a conventional method for preparing a decoction of a Chinese medicine, i.e., the raw materials are decocted into a decoction by adding water.
EXAMPLE 12 clinical efficacy test
1 clinical data
1.1 general data
120 chronic heart failure patients who are hospitalized in the traditional Chinese medicine hospital of Union, 2019, 1 month to 2020, and 12 months are continuously collected, and are randomly (by a random digital table method) divided into a test group and a control group, 60 patients respectively. The patients' left heart function NYHA is classified into II-IV. The test group comprises 60 patients, wherein 30 men and 30 women are aged 44-81 years, the average (70.33 +/-8.98) years, 7 patients with cardiac function II, 39 patients with III, 14 patients with IV, 48 patients with ACEI/ARB/ARNI tolerance and 52 patients with beta-blocker tolerance. Control group of 60 patients, 30 males, 30 females, age 43-81, mean age (71.60 + -9.50) years, 11 cardiac function class II, 36 class III, 13 class IV, 50 tolerant to ACEI/ARB/ARNI, 53 tolerant to beta blockers. The heart failure patients in the test group and the control group have no significant difference in sex, age and disease course (P is more than 0.05), and the patients in the two groups receive standard anti-heart failure treatment medicaments. This study was approved by the institutional medical ethics committee.
1.2 inclusion criteria
Meets the diagnosis standard of chronic heart failure formulated by 'Chinese heart failure diagnosis and treatment guide 2018'; the heart function classification conforms to the classification standards II-IV of the New York Heart Association (NYHA); according to the guideline of clinical research on new drugs in Chinese medicine, the clinical syndrome differentiation is qi deficiency and water retention syndrome, the age is 18-85 years, and the informed consent is signed.
1.3 exclusion criteria
(1) Acute myocardial infarction, hypertrophic cardiomyopathy, constrictive pericarditis, obvious valvular lesion or congenital heart disease, primary pulmonary hypertension or secondary severe pulmonary hypertension;
(2) Ischemic heart failure is not subjected to revascularization or is less than 3 months after revascularization;
(3) Acute myocardial infarction occurs within nearly 3 months;
(4) Patients with acute pulmonary edema or acute hemodynamic disorders;
(5) A patient prepared for heart transplant or CRT, or who has received CRT treatment;
(6) The systolic pressure is more than 180mmHg;
(7) Severe electrolyte disturbance combined with severe impairment of liver and kidney functions;
(8) Right heart failure due to pulmonary disease.
1.4 methods of treatment
The two groups are treated with western medicine (including ACEI/ARB/ARNI, diuretic, BETA receptor blocker, etc.); after random grouping, the control group was administered placebo (one tenth of the flavored up-endemic soup) and the test group was administered flavored up-endemic soup, with a single blind method, recipe: 18g of astragalus root, 10g of rhizoma anemarrhenae, 15g of polyporus, 6g of radix bupleuri, 6g of platycodon grandiflorum, 4g of rhizoma cimicifugae, 15g of semen lepidii and the like, 1 dose per day, 100ml of each of which is taken 2 times in the morning and at night. Both treatment courses were 12 weeks.
1.5 Observation index
Adverse reactions of the drugs are evaluated according to the clinical drug adverse reaction dictionary during the medication period, the changes of heart rate and blood pressure are strictly monitored, the routine detection of liver and kidney functions and blood is performed, and the occurrence conditions of adverse reactions of the drugs are recorded in detail and timely symptomatic treatment is performed. The integral of the syndrome of traditional Chinese medicine is calculated by referring to the guiding principle of clinical research of new traditional Chinese medicine. Changes in 6MWT, NT-proBNP levels and LVEF were observed before and 12 weeks after treatment in both groups.
1.6 statistical methods
Analyzing and measuring by SPSS22.0 statistical softwareData are normally distributed with mean + -standard deviation
Expressed as median (M) (25% percentile (Q1), 75% percentile (Q3)) using the t-test, for non-normal distributions, using the Mann-WhitneyU test; the data of the counting is as follows 2 The test shows that the difference is statistically significant when P is less than 0.05.
2 results
2.1 integral comparison of Chinese medical symptoms before and after treatment of two groups of patients
According to the guideline of clinical research of new Chinese medicine, the Chinese medicine symptom integral is calculated according to the severity of heart failure main symptoms (chest distress, asthma, edema and palpitation) and secondary symptoms (listlessness, idle speaking, spontaneous perspiration and shortness of breath) which are divided into 4 grades, no-0 score, light-2 score, medium-4 score and heavy-6 score. And (4) prompting by a result: the symptoms of chest distress, asthma, edema, palpitation, listlessness, no talk, spontaneous perspiration and short breath in the two groups before treatment are compared, and the difference is not significant (P is more than 0.05). After the treatment of the test group, the symptoms of chest distress, asthma, edema, palpitation, lassitude, no speaking desire, spontaneous perspiration and shortness of breath are compared, and the difference before and after the treatment has statistical significance (P is less than 0.05); the total integral of the traditional Chinese medicine symptoms of the two groups of patients is obviously reduced before and after treatment, and the reduction of the test group is more obvious (P is less than 0.05). See table 1 for details.
TABLE 1 comparison of Chinese medicine symptom integrals before and after treatment of two groups of patients
Note: compared with the treatment before the treatment, ※ P<0.05; compared with the control group, the compound is added, # P<0.05。
2.2 Pre-and post-treatment 6MWT comparisons of two groups
Before treatment, the difference was not statistically significant (P > 0.05) when 6MWT was compared between the two groups of patients. After treatment, the 6MWT increased significantly in both groups, and the test group increased more significantly (P < 0.05). See table 2.
Table 2 pre-and post-treatment 6MWT comparisons of the two groups (rice,
)
| group of | Number of examples | Before treatment | After treatment |
| Test group | 60 | 291.00±78.01 | 356.33±81.15 ※# |
| Control group | 60 | 305.82±91.82 | 353.83±96.82 ※ |
Note that compared to the treatment before, ※ P<0.05; compared with the control group, the compound of the formula, # P<0.05。
2.3 comparison of NT-proBNP before and after treatment of the two groups
Before treatment, the difference between NT-proBNP in the two groups of patients was not statistically significant (P > 0.05). The comparative reduction range of NT-proBNP of the two groups of patients before and after treatment is more than 30 percent, and both the two groups of patients achieve ideal treatment targets. After treatment, the NT-proBNP in the two groups is greatly reduced, and the reduction in the experimental group is more obvious (P < 0.05). See table 3.
TABLE 3 two-panel pre-and post-treatment NT-proBNP comparison (pg/ml, M (min, max))
| Group of | Number of examples | Before treatment | After treatment |
| Test group | 60 | 2078(1379,4338) | 705.5(305,1319.5) ※# |
| Control group | 60 | 1843(1316,4001) | 884.5(570.75,1710) ※ |
Note that compared with the treatment before the treatment, ※ P<0.05; compared with the control group, the compound of the formula, # P<0.05。
2.4 comparison of LVEF before and after treatment of two groups
Before treatment, the LVEF difference between the two groups of patients was not statistically significant (P > 0.05). After treatment, LVEF was significantly elevated in both groups, with the test group elevated more significantly (P < 0.05). See table 4.
Table 4 comparison of LVEF before and after treatment of the two groups (%,
)
| group of | Number of examples | Before treatment | After treatment |
| Test group | 60 | 47.95±9.25 | 56.04±9.15 ※# |
| Control group | 60 | 49.71±9.45 | 54.92±9.10 ※ |
Note that compared to the treatment before, ※ P<0.05; compared with the control group, the compound of the formula, # P<0.05。
2.5 comparison of left Heart function NYHA rating before and after treatment in two groups of patients
After treatment, the cardiac function of the patients in the test group is obviously improved, 13 patients with central function IV are reduced, the cardiac function of the patients in the test group is better than that of the patients in the control group after treatment, and the difference has statistical significance (P < 0.05). See table 5.
TABLE 5 comparison of left Heart function NYHA rating before and after treatment in two groups of patients (example (%))
The cardiac function efficacy was assessed according to the NYHA classification method. (1) The heart function is controlled basically or improved by more than 2 grades. (2) improving effective cardiac function by 1 grade but less than 2 grade. (3) the improvement of ineffective cardiac function is less than grade 1. (4) deterioration of cardiac function at 1 level or more than 1 level. The total effective rate of the test group is 73.4 percent, the total effective rate of the control group is 58.3 percent, and compared between the two groups, the difference has statistical significance (P is less than 0.05). See table 6.
TABLE 6 comparison of clinical efficacy of two groups of patients (example (%))
| Group of | Number of examples | Show effect | Is effective | Invalidation | Deterioration of |
| Test group | 60 | 7(11.7) | 37(61.7) | 16(26.7) | 0(0) |
| Control group | 60 | 9(15) | 26(43.3) | 23(38.3) | 0(0) |
Note that P <0.05 compared to control.
2.6 results of safety evaluation before and after treatment of two groups of patients
Before and after treatment, serious adverse reactions do not occur in the two groups of patients through dynamic observation of liver and kidney functions, blood routine and the like, and the incidence rate of gastrointestinal reaction of the patients in the test group is obviously lower than that of the patients in the control group.
Example 13 animal models
1 materials and methods
1.1 drugs and reagents
The preparation of the traditional Chinese medicine composition I comprises the following steps: the raw materials are weighed according to the weight part ratio of the pharmaceutical composition in the embodiment 1, and are decocted with water to form decoction for preparation.
The preparation of the traditional Chinese medicine composition II comprises the following steps: the raw materials are weighed according to the weight part ratio of the pharmaceutical composition in the embodiment 2, and are decocted with water to form decoction for preparation.
Preparing a first traditional Chinese medicine composition of a control group: weighing 18 parts of astragalus mongholicus, 15 parts of semen lepidii, 15 parts of polyporus umbellatus, 10 parts of rhizoma anemarrhenae, 6 parts of bark of schefflera octophylla, 6 parts of platycodon grandiflorum and 4 parts of radix peucedani praeruptorum, and adding water to decoct into decoction for preparation.
Preparing a control group traditional Chinese medicine composition II: weighing 18 parts of astragalus, 15 parts of semen lepidii, 15 parts of polyporus umbellatus, 10 parts of cassia occidentalis, 6 parts of rhizoma cimicifugae, 6 parts of platycodon grandiflorum and 4 parts of decursia violacea according to the weight part ratio, and adding water to decoct into decoction for preparation.
Reagent: doxorubicin hydrochloride (shanghai-derived leaf biotechnology, ltd.), physiological saline (shanghai-research industries, ltd.), BNP (ELISA) kit (shanghai-research biotechnology, ltd).
1.2 Instrument
PL-203 type electronic balance (mettler-toledo instruments (shanghai) ltd); DW-86L626 type ultra-low temperature refrigerator (Haier Co., ltd.); a SUNRISE type microplate reader (Tecan, switzerland); a neogauge 15R type bench top high speed refrigerated centrifuge (Healforce); electrocardiographs (Beijing Futian electronic medical instruments, inc.).
1.3 animals
SPF grade SD rats, 180-200g,70 in body mass, half female and half male, were provided by Shanghai Si Laike laboratory animal services, inc.
2 protocol for the experiment
2.1 modeling of Heart failure (CHF) animals
The doxorubicin rat cardiomyopathy and congestive heart failure models established by documents (Li Yuling, yang Jianye, tang Junming, etc., comparison of different schemes of doxorubicin-induced rat heart failure models, china journal of comparative medicine 2006.16 (2): 93-96.) were prepared into 2mg ml with water for injection -1 Solution, according to 4mg.kg -1 Body weight, i.e. 2mL.kg -1 SD rats were injected intraperitoneally 1 time per week for 6 weeks, and the total amount was 24mg -1 Body weight. After 6 weeks, the T wave height rising of the ST section of the electrocardiogram raised with the II leads of the limbs is detected to be successful in modeling.
2.2 grouping and administration
Randomly selecting 50 rats successfully modeled into 6 groups, each group comprises 10 rats with half male and half female, namely the first group of the invention, the second group of the invention, the first control group, the second control group and the model group, selecting 10 rats without modeling as blank groups, and continuously administering for 4 weeks according to the following mode:
the invention comprises the following components: the decoction prepared by the group I of the invention is used for intragastric administration twice a day, and the concentration is 10mL/kg
The invention has the following group two: the decoction prepared by the second group of the invention is used for intragastric administration twice a day, and the concentration is 10mL/kg.
Control group one: the decoction prepared by the control group I is perfused twice a day, 10mL/kg.
Control group two: the decoction prepared by the control group II is infused twice a day, 10mL/kg.
Model group: the stomach is irrigated twice daily according to 10mL/kg drinking water.
2.3 detection of indicators
2.3.1 comparison of Heart Mass and Heart Rate in groups of rats
The heart mass and the heart rate of each group of rats after administration are measured, and the influence of the formulation for promoting urination with the liter sinking on the heart mass and the heart rate of the rats is reflected.
2.3.2 detection of BNP in groups of rats
BNP detection adopts an ELISA method: weighing all animals after administration, collecting blood via orbital vein, standing whole blood sample at room temperature for 2 hr, centrifuging for 10min at 3000r/min, collecting serum as sample, and freezing at-80 deg.C. The detection steps are carried out strictly according to the kit instructions.
3. Statistical treatment
All data of the animal experiment are analyzed by adopting an SPSS23.0 statistical software package, the metering data are expressed by mean +/-standard deviation (x +/-s), two-to-two comparison among groups adopts chi-square test and t test, and the difference of p less than 0.05 has statistical significance.
4 results
4.1 Effect on rat Heart Mass and Heart Rate
The heart mass and heart rate of the rats after the end of the administration are shown in table 7, wherein the heart mass of the rats in the model group is remarkably reduced (p < 0.05) compared with that in the blank group, and the heart mass is increased (p < 0.01) after the administration compared with that in the model group; the heart rate of rats in the model group was significantly increased (p < 0.01) compared to the blank group, and the heart rate after administration was decreased (p < 0.01) compared to the model group.
TABLE 7 rat cardiac mass and Heart Rate variability
Note: comparison with blank group 1) (p<0.01)， 3) (p<0.05 ); in comparison with the set of models, 2) (p<0.01)， 4) (p<0.05)
4.2 comparison of BNP in groups of rats
BNP levels in rats of each group are as in table 8, and BNP levels in the model group are significantly increased (p < 0.05) compared to the blank group; the BNP level was significantly reduced after drug treatment compared to the model group (p < 0.05).
TABLE 8 comparison of the levels of BNP
| Group of | n (example) | BNP((pg/ml) |
| The invention is combined into | 10 | 23.15±1.14 2) |
| Invention group two | 10 | 24.43±2.87 |
| Control group one | 10 | 34.26±2.67 |
| Control group two | 10 | 41.63±1.33 |
| Model set | 10 | 49.64±2.09 1) |
| Blank group | 10 | 16.97±1.67 |
Note: comparison with blank group 1) (p<0.05 ); in comparison with the set of models, 2) (p<0.05)
in conclusion, the traditional Chinese medicine compositions of the invention group and the control group have different treatment effects on CHF rats and can improve the cardiac function of the CHF rats, wherein the treatment effect of the first group is the most prominent.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.
Claims (5)
1. The traditional Chinese medicine composition for treating chronic heart failure is characterized by being prepared from the following raw material medicines in parts by weight: 14-22 parts of astragalus, 11-19 parts of semen lepidii, 11-19 parts of polyporus umbellatus, 6-14 parts of rhizoma anemarrhenae, 2-10 parts of radix bupleuri, 2-10 parts of platycodon grandiflorum and 1-8 parts of cimicifugae foetidae.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 16-20 parts of astragalus membranaceus, 13-17 parts of semen lepidii, 13-17 parts of polyporus umbellatus, 8-12 parts of rhizoma anemarrhenae, 4-8 parts of radix bupleuri, 4-8 parts of platycodon grandiflorum and 2-6 parts of rhizoma cimicifugae.
3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 18 parts of astragalus, 15 parts of pepperweed seed, 15 parts of polyporus, 10 parts of rhizoma anemarrhenae, 6 parts of radix bupleuri, 6 parts of platycodon grandiflorum and 4 parts of cimicifugae foetidae.
4. Use of the Chinese medicinal composition of any one of claims 1-3 in the preparation of a medicament for the treatment of chronic heart failure.
5. The use according to claim 4, wherein the chronic heart failure is chronic heart failure of the qi-deficiency water-stop type.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211537001.0A CN115969928A (en) | 2022-12-02 | 2022-12-02 | Traditional Chinese medicine composition for treating chronic heart failure and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211537001.0A CN115969928A (en) | 2022-12-02 | 2022-12-02 | Traditional Chinese medicine composition for treating chronic heart failure and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115969928A true CN115969928A (en) | 2023-04-18 |
Family
ID=85972916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211537001.0A Pending CN115969928A (en) | 2022-12-02 | 2022-12-02 | Traditional Chinese medicine composition for treating chronic heart failure and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115969928A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116549583A (en) * | 2023-05-16 | 2023-08-08 | 河南中医药大学第一附属医院 | Traditional Chinese medicine composition for ascending, removing stasis and dissolving turbidity as well as preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619367A (en) * | 2018-06-26 | 2018-10-09 | 中国人民解放军第二军医大学第二附属医院 | A kind of Chinese medicine composition is preparing the application in preventing the drug of Acute cardiotoxicity caused by adriamycin |
-
2022
- 2022-12-02 CN CN202211537001.0A patent/CN115969928A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619367A (en) * | 2018-06-26 | 2018-10-09 | 中国人民解放军第二军医大学第二附属医院 | A kind of Chinese medicine composition is preparing the application in preventing the drug of Acute cardiotoxicity caused by adriamycin |
Non-Patent Citations (2)
| Title |
|---|
| 姚磊;柏永辉;陆文杰;石亚楠;符德玉;: "升陷汤在慢性左心衰患者中的临床疗效评价和药物安全性研究", 中药材, vol. 43, no. 02, pages 478 - 481 * |
| 徐基杰;瞿惠燕;王英杰;封舟;刘茜;黄牧华;杨涛;周华;: "黄芪葶苈子配伍治疗慢性心力衰竭Meta分析", 中医学报, vol. 32, no. 08, pages 1483 - 1486 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116549583A (en) * | 2023-05-16 | 2023-08-08 | 河南中医药大学第一附属医院 | Traditional Chinese medicine composition for ascending, removing stasis and dissolving turbidity as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111658701A (en) | Spleen-tonifying traditional Chinese medicine composition and application thereof | |
| CN115969928A (en) | Traditional Chinese medicine composition for treating chronic heart failure and application thereof | |
| CN111643591A (en) | Traditional Chinese medicine composition for tonifying spleen and kidney and application thereof | |
| CN111729064A (en) | Traditional Chinese medicine composition for invigorating spleen and activating yang and application thereof | |
| CN100475263C (en) | Medicine for treating chronic obstructive lung disease and preparation method thereof | |
| CN111905051A (en) | Traditional Chinese medicine composition with functions of preventing and treating chronic heart failure, qi and yin deficiency, blood stasis and water retention syndrome and preparation method and application thereof | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN113559223B (en) | Traditional Chinese medicine compound composition for treating chronic heart failure and preparation method thereof | |
| CN101543574B (en) | Chinese medicinal composition for treating pulmonary interstitial fibrosis | |
| CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN102309669B (en) | Chinese medicinal preparation for treating allergic conjunctivitis | |
| CN104352797A (en) | Traditional Chinese medicine for treating advanced lung cancer and application of traditional Chinese medicine | |
| CN109498739B (en) | Traditional Chinese medicine composition for treating coronary heart disease and heart failure and preparation method thereof | |
| CN116808162B (en) | Traditional Chinese medicine composition for preventing and treating ventricular premature contraction due to stagnation of gallbladder and phlegm and application thereof | |
| CN116059292B (en) | Traditional Chinese medicine composition for treating heart failure and preparation process thereof | |
| CN102580037B (en) | Chinese medicinal composition for treating cough caused by cold-type infection and preparation method thereof | |
| CN102240359B (en) | Traditional Chinese medicine for preventing and treating recurrence of esophageal cancer after radiotherapy and resisting side reactions of radiotherapy | |
| CN112741872B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101244127B (en) | Medicament for treating vascular dementia | |
| CN100443093C (en) | AIDS treating medicine | |
| CN101843681B (en) | Application of composite containing polygonum orientale in preparing medicaments for preventing and treating diabetes and complication thereof | |
| CN118286345A (en) | Traditional Chinese medicine composition for treating AIDS complicated with pneumosporosis pneumonia | |
| CN101612209B (en) | Application of compound oriental smartweed preparation in preparing medicaments for preventing and treating diabetes mellitus and complicating diseases thereof | |
| CN113171437A (en) | Application of bupleurum tenue composition in preparing antiviral preparation for resisting coronavirus | |
| CN111110815A (en) | Spleen-warming and blood sugar-reducing granules and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |